Celvan
The computed 12-month bankruptcy probability of Celvan is 0.2% (very low). The 2025 annual accounts show equity of €6k and a net result of €120k. Equity is shrinking by ~32.5% per year and would, assuming unchanged policy, indicatively turn negative around fiscal year 2027. Its solvency ranks better than 12% of 2187 sector peers (fiscal year 2025). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €6k |
| Net result | €120k |
| Better than sector | 12% |
| Active | 2 yrs |
Strong profile, led by profitability.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 2.1% | 58.1% | |
| Net result | €120k | €60k | |
| Equity | €6k | €74k | |
| Gross operating margin | €163k | €96k | |
| Total assets | €268k | €186k |
| Fiscal year | 2025 |
|---|---|
| Revenue | - |
| EBITDA | €163k |
| Net profit | €120k |
| Cash flow | €129k |
| Staff costs | - |
| Income taxes | €35k |
| Dividends | €225k |
| Total assets | €268k |
| Equity | €6k |
| Debt | €262k |
| of which ≤ 1y | €262k |
| of which > 1y | - |
| Working capital | €-20k |
| Employees (FTE) | - |
| 2025 | |
|---|---|
| Current ratio | 0.92 |
| Quick ratio | 0.92 |
| Working capital ratio | -7.4% |
| Solvency | 2.1% |
| Debt / equity | 45.90 |
| Long-term debt ratio | - |
| Interest coverage | 281.42 |
| Gross margin | - |
| Net margin | - |
| ROA | 44.9% |
| ROE | 2106.4% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €268k |
| Fixed assets | 21/28 | €26k |
| Tangible fixed assets | 22/27 | €26k |
| Financial fixed assets | 28 | €25 |
| Current assets | 29/58 | €242k |
| Amounts receivable within one year | 40/41 | €49k |
| Investments | 50/53 | €12k |
| Cash & bank | 54/58 | €180k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €268k |
| Equity | 10/15 | €6k |
| Contributions / capital | 10/11 | €5k |
| Reserves | 13 | €305 |
| Accumulated profits (losses) | 14 | €0 |
| Amounts payable | 17/49 | €262k |
| Amounts payable within one year | 42/48 | €262k |
| Trade debts payable within one year | 44 | €153 |
| Income statement | ||
| Gross operating margin | 9900 | €163k |
| Operating result | 9901 | €154k |
| Financial income | 75 | €1k |
| Financial charges | 65 | €578 |
| Result before taxes | 9903 | €155k |
| Income taxes | 67/77 | €35k |
| Net result for the period | 9904 | €120k |
| Result to be appropriated | 9905 | €120k |
| NACE primary | General medical practice(86210) |
| Legal form | Private limited company(610) |
| Incorporation | 22-09-2023 |
| Status | Active |
| Postal code | 2570 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 12302B0151/00E000 | Flanders | 1,593 m² | 1 · 197 m² | 10.4 m · 3 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
11-12-2025 Registered office moved from Kontich to Duffel
- Bautersemstraat 101, 2550 Kontich → Binnenweg 201, 2570 Duffel
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "statutaire",
"new_address": {
"city": "Duffel",
"region": null,
"street": "Binnenweg",
"country": "BE",
"postcode": "2570",
"box_number": null,
"street_number": "201"
},
"old_address": {
"city": "Kontich",
"region": null,
"street": "Bautersemstraat",
"country": "BE",
"postcode": "2550",
"box_number": null,
"street_number": "101"
},
"effective_date": "2025-12-01",
"evidence_quote": "De enige bestuurder bevestigt hierbij de beslissing tot verplaatsing van het adres van de zetel met ingang vanaf 1 december 2025 naar: Binnenweg 201 2570 Duffel"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "1000.161.060",
"name_full": "CELVAN",
"legal_form": "BV"
}
}26-09-2023 Incorporation of a new BV
Technical details
{
"kind": "oprichting",
"seat": "2550 Kontich, Bautersemstraat 101",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1996-08-11",
"name": "Vanderhaeghe C\u00E9line",
"niss": null,
"address": "2550 Kontich, Bautersemstraat 101"
},
"share_class": "Ordinary",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 5400,
"holder_person_name": "Vanderhaeghe C\u00E9line",
"is_subscriber_only": false,
"n_shares_subscribed": 180,
"amount_subscribed_eur": 5400,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 5400,
"subject_company": {
"kbo": "1000.161.060",
"name_full": "Celvan",
"legal_form": "BV"
},
"initial_directors": [],
"incorporation_date": "2023-09-21",
"post_incorporation_mandates": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | Celvan |